Blanche Mavromatis, MD
Hematology & Oncology · Washington, DCNPI 1336137876
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Seagen Inc. accounts for 68.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $9,180 and has fallen 93.6% since, to $584 in 2025.
Across 74 payments — averaging $179.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$9K
- Bristol Myers Squibb$1K
- Johnson & Johnson$1K
- AstraZeneca$178
- Gilead$159
- Pfizer$152
- plus $1K from 20 others
Across 69 payments — averaging $2461.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$147K
- Pharmacyclics LLC, An Abbvie Company$11K
- E.r. Squibb & Sons, L.L.C.$10K
- Novartis$2K
- AbbVie$700
What the payments were for
- Consulting fees$2,33818%
- Speaking & faculty fees$7,26055%
- Travel & lodging$1,61712%
- Food & beverage$1,81314%
- Education$2802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 8 | $9,045 |
| Bristol Myers Squibb | 8 | $1,472 |
| Johnson & Johnson | 6 | $1,191 |
| AstraZeneca | 4 | $178 |
| Gilead | 2 | $159 |
| Pfizer | 7 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $146 |
| Immunogen, Inc. | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 7 | $111 |
| Daiichi Sankyo Inc. | 5 | $107 |
| Bayer | 3 | $104 |
| Incyte Corporation | 1 | $94 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $90 |
| Astellas Pharma US Inc | 4 | $78 |
| GSK | 2 | $43 |
| Array Biopharma Inc | 2 | $39 |
| Caris MPI, Inc. | 1 | $36 |
| Amgen | 1 | $24 |
| Tempus AI, Inc | 1 | $19 |
| EMD Serono, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,308 in reported general payments places this provider in the 70th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 37 | $592,719 |
| RevlimidLenalidomide | 23 | $430,695 |
| OrserduElacestrant Hcl | 15 | $349,141 |
| Lenalidomide | 24 | $336,213 |
| JakafiRuxolitinib Phosphate | 15 | $263,427 |
| TagrissoOsimertinib Mesylate | 13 | $211,232 |
| ImbruvicaIbrutinib | 12 | $195,988 |
| NinlaroIxazomib Citrate | 11 | $136,473 |
| EliquisApixaban | 35 | $28,419 |
| Imatinib Mesylate | 25 | $12,134 |
| XareltoRivaroxaban | 11 | $11,325 |
| Enoxaparin Sodium | 14 | $10,416 |
| Exemestane | 11 | $2,670 |
| Letrozole | 74 | $2,456 |
| ValacyclovirValacyclovir Hcl | 18 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $152 | $621,13872 claims |
| Bristol Myers SquibbRevlimid | $1,472 | $430,69523 claims |
| Incyte CorporationJakafi | $94 | $263,42715 claims |
| AstraZenecaTagrisso | $178 | $211,23213 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $90 | $195,98812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $146 | $136,47311 claims |
| Johnson & JohnsonXarelto | $1,191 | $11,32511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.